Ting Therapeutics, Inc.

San Diego, CA

UEI
F5R2ZH3HCHB5
CAGE
89RT3
Primary NAICS
325412 Pharmaceutical Preparation Manufacturing
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Physical address
6868 Nancy Ridge Dr, San Diego, CA 92121, USA

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Grant awards

Award Agency Obligated Awarded
Effect of afatinib against noise-induced hearing loss HT94252310876 Defense Health Agency $349,658
Therapeutics to prevent aminoglycoside-induced hearing loss R44DC019065 National Institute on Deafness and Other Communincation Disorders (NIH) $1,572,901
Therapeutics to prevent aminoglycoside-induced hearing loss R43DC019065 National Institute on Deafness and Other Communincation Disorders (NIH) $206,749
Preclinical evaluation of an otoprotectant TT002 R44DC018762 National Institute on Deafness and Other Communincation Disorders (NIH) $4,269,963
Therapeutics to prevent cisplatin-induced hearing loss by transcriptomics R43DC018762 National Institute on Deafness and Other Communincation Disorders (NIH) $200,486

Latest 5 listed here. See the rest on GovTribe.

Similar vendors

Vendor Location Primary NAICS
Jacaranda Biosciences, Inc. UEI MKHLELWDN7D7 San Francisco, CA —
Gateway Biotechnology, Inc. UEI XDDXGL6JRRD9 Olivette, MO 541714 Research and Development in Biotechnology (except Nanobiotechnology)
Senseion Therapeutics Inc. UEI V2KQH21BGKY5 St. Louis, MO 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Instituto De Investigaciones En Ingenieria Genetica Y Biologia Molecular UEI RL5ND2BM4NL7 Buenos Aires, CABA 541714 Research and Development in Biotechnology (except Nanobiotechnology)
Max Biopharma, Inc. UEI NZ8XY5DKRAD3 Santa Monica, CA 541714 Research and Development in Biotechnology (except Nanobiotechnology)

See more similar vendors on GovTribe

About the company

Written by GovTribe AI ·

Ting Therapeutics LLC is a pharmaceutical company that develops drugs to prevent and treat hearing loss. The company provides drug development services to the federal government through research grants from the National Institutes of Health to discover and test potential otoprotectant drugs.

Specifically, Ting Therapeutics has received seven federal grants totaling over $9 million from the National Institute on Deafness and Other Communication Disorders to support preclinical research on drug candidates for preventing cisplatin-induced hearing loss and noise-induced hearing loss. Services provided through these grants include in vitro and in vivo screening and testing in mouse and guinea pig models to evaluate the efficacy, pharmacokinetics, pharmacodynamics, and safety of Ting's lead drug candidates TT001 and TT002. The research also evaluates any potential interference of these drug candidates on the antitumor efficacy of cisplatin. By successfully completing the aims of these grants, Ting Therapeutics gathers critical preclinical data needed to support future Investigational New Drug applications and clinical trials, with the long-term goal of commercializing TT001 and TT002 as otoprotectants for patients receiving cisplatin cancer therapy.

Quick answers

Is Ting Therapeutics, Inc. registered in SAM.gov?

Yes. Ting Therapeutics, Inc.'s SAM.gov registration is active through August 18, 2027.

What is Ting Therapeutics, Inc.'s most recent federal award?

Ting Therapeutics, Inc.'s most recent federal grant award is Effect of afatinib against noise-induced hearing loss (HT94252310876), from Defense Health Agency, on September 1, 2023.

On GovTribe

See Ting Therapeutics, Inc.'s full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login